VNDA vs ZBH: fair value comparison
Vanda Pharmaceuticals Inc. and Zimmer Biomet Holdings, Inc. · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, VNDA currently sits closer to the top of our discount ranking. ZBH carries the stronger quality grade.
| VNDA | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $5.23 | $100.91 |
| 12-month range | $4.47–$8.25 | $82.90–$105.01 |
| Sector rank | #36 of 113 Healthcare | #40 of 113 Healthcare |
| Quality grade | D | B |
| Momentum grade | — | B |
| Leverage | Low | Moderate |
| Margin trend | — | Stable |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Undervalued |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: VNDA fair value analysis · ZBH fair value analysis